H Sinzinger1, J O'Grady. 1. Wilhelm Auerswald Atherosclerosis Research Group (ASF) Vienna, Institute for Diagnosis and Treatment of Atherosclerosis and Lipid Disorders (ATHOS), Vienna, Austria. helmut.sinzinger@univie.ac.at
Abstract
AIMS: Muscular problems are the major group of side-effects during statin treatment. They are known to occur much more frequently during and after exercise. METHODS AND RESULTS: For the last 8 years we have monitored 22 professional athletes in whom, because of familial hypercholesterolaemia, treatment with different statins was attempted. Only six out of the 22 finally tolerated at least one member of this family of drugs. In three of these six the first statin prescribed allowed training performance without any limitation. Changing the drug demonstrated that only two tolerated all the four or five statins examined (atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin). Cerivastatin was not among the statins prescribed. CONCLUSIONS: These findings indicate that in top sports performers only about 20% tolerate statin treatment without side-effects. Clinical decision making as to lipid lowering therapy thus becomes a critical issue in this small subgroup of patients.
AIMS: Muscular problems are the major group of side-effects during statin treatment. They are known to occur much more frequently during and after exercise. METHODS AND RESULTS: For the last 8 years we have monitored 22 professional athletes in whom, because of familial hypercholesterolaemia, treatment with different statins was attempted. Only six out of the 22 finally tolerated at least one member of this family of drugs. In three of these six the first statin prescribed allowed training performance without any limitation. Changing the drug demonstrated that only two tolerated all the four or five statins examined (atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin). Cerivastatin was not among the statins prescribed. CONCLUSIONS: These findings indicate that in top sports performers only about 20% tolerate statin treatment without side-effects. Clinical decision making as to lipid lowering therapy thus becomes a critical issue in this small subgroup of patients.
Authors: Paul S Phillips; Richard H Haas; Sergei Bannykh; Stephanie Hathaway; Nancy L Gray; Bruce J Kimura; Georgirene D Vladutiu; John D F England Journal: Ann Intern Med Date: 2002-10-01 Impact factor: 25.391
Authors: Jacob P Kelly; Allison Dunning; Phillip J Schulte; Mona Fiuzat; Eric S Leifer; Jerome L Fleg; Lawton S Cooper; Steven J Keteyian; Dalane W Kitzman; Ileana L Pina; William E Kraus; David J Whellan; Christopher M O'Connor; Robert J Mentz Journal: JACC Heart Fail Date: 2016-07-06 Impact factor: 12.035
Authors: Beth A Parker; Jeffrey A Capizzi; Amanda L Augeri; Adam S Grimaldi; C Michael White; Paul D Thompson Journal: Atherosclerosis Date: 2011-10-04 Impact factor: 5.162
Authors: Catherine R Mikus; Leryn J Boyle; Sarah J Borengasser; Douglas J Oberlin; Scott P Naples; Justin Fletcher; Grace M Meers; Meghan Ruebel; M Harold Laughlin; Kevin C Dellsperger; Paul J Fadel; John P Thyfault Journal: J Am Coll Cardiol Date: 2013-04-10 Impact factor: 24.094